In order to evaluate the sotorasib safety profile, the Phase 1/2 CodeBreaK 100 clinical trial was initiated in 2018, first enrolling patients with KRAS p.G12C-mutated solid tumors, and subsequently focusing on those with KRAS p.G12C-mutated NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.